Valporate report

That this House expresses deep concern at the continuing impact on individuals and families affected by harm linked to prenatal exposure to sodium valproate; notes that the Patient Safety Commissioner published a report in February 2024 outlining options for a two-stage approach to potential redress for those affected; further notes that families continue to report significant physical, neurodevelopmental, educational and social challenges arising from this harm; recognises the frustration expressed by affected families and campaigners at the lack of a substantive Government response; and calls on His Majesty’s Government to give full and urgent consideration to the findings and recommendations of the Patient Safety Commissioner’s report and to set out in due course how it intends to respond.